NeurologyLive® Friday 5 — September 11, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more or watch now buttons for more details and information about each highlight.

1: Gray Areas: Animal Models vs iPSC for Neuropathy Research

Episode 1 features a conversation with Ahmet Hoke, MD, PhD, of Johns Hopkins Medicine, who discussed the clinical debate behind keeping animal models for neuropathy research vs switching to induced pluripotent stem cell models.

2: Differentiating Agitation from Depression, Anxiety, and Psychosis

Distinguishing agitation from depression, anxiety, and psychosis shapes everything that follows in treatment. The panel of Alzheimer disease experts walked through the clinical differences and where formal screening scales genuinely fit into daily practice.

3:Addressing the Comorbidity Burden in Epilepsy

Beyond seizure control, Jacqueline French, MD, examined how clinicians can more proactively uncover psychiatric, cognitive, behavioral, sleep, and other comorbidities that shape the lives of patients with epilepsy.

4: NeuroVoices: Jacqueline Becker, PhD, on Brain Fog, Alzheimer Risk, and Treatment Advances in Long COVID

In our latest NeuroVoices, Jacqueline Becker, PhD, clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai, discussed the mechanisms behind brain fog from Long COVID and its potential links to Alzheimer risk.

5: Dual Therapy and the Changing Treatment Landscape of SMA

In this Mind Moments episode, Aaron Zelikovich, MD, a neuromuscular physician at Lenox Hill Hospital, part of Northwell Health, joins the podcast to discuss the emerging conversation around dual therapy in spinal muscular atrophy (SMA).

Don’t have time to read or watch a full video interview? Click here to check out our shorts!